Welcome to our dedicated page for Gohealth SEC filings (Ticker: GOCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoHealth, Inc. filings document the public-company record for a Medicare-focused digital health and insurance marketplace. Its 8-K reports cover operating results, financial-condition updates, capital and credit arrangements, and material agreements, including secured term-loan financing involving GoHealth subsidiaries such as Norvax, LLC.
Proxy and governance filings describe annual meeting proposals, director elections, executive compensation votes, incentive-plan matters, auditor ratification, board appointments, committee roles, and stockholder voting results. The filing record also includes capital-structure disclosures, risk and liquidity context tied to Medicare Advantage conditions, and Nasdaq continued-listing compliance notices for GOCO common stock.
GoHealth, Inc. reports first-quarter 2026 net revenues of $11.9 million, down sharply from $221.0 million a year earlier, and a net loss of $66.1 million. The loss reflects much lower Medicare revenue and high operating costs, especially general and administrative expenses and interest on heavy debt.
Cash was $39.9 million as of March 31, 2026 against term loan facilities of $701.8 million, and management discloses substantial doubt about the company’s ability to continue as a going concern because of tightening minimum liquidity covenants. GoHealth is negotiating strategic alternatives with lenders while also facing ongoing False Claims Act litigation in which the Department of Justice has intervened.
GoHealth, Inc. notified the SEC that it could not file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 on time because it is engaged in ongoing discussions with lenders and stakeholders about strategic alternatives, which may involve a change of control or restructuring.
The company says additional time was required to compile and analyze information and finalize disclosures tied to those discussions. The filing states that revenues for the three months ended March 31, 2026 have declined versus the same period in 2025.
GoHealth, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026. Investors will elect three Class III directors, ratify Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and cast an advisory say‑on‑pay vote on named executive officer compensation.
As of April 22, 2026, voting securities included 50,000 shares of Series A Convertible Perpetual Preferred Stock, 16,686,419 shares of Class A common stock and 12,616,074 shares of Class B common stock. CEO Vijay Kotte received 2025 total compensation of $13,757,255, while Ernst & Young LLP billed 2025 audit and related fees of $3,824,769 and tax fees of $139,985.
GoHealth, Inc. operates a Medicare-focused digital health insurance marketplace, matching U.S. seniors to Medicare Advantage, Supplement and prescription drug plans using a data- and AI-driven platform and licensed agents. The company also offers GoHealth Protect products for unexpected life events, including guaranteed acceptance life insurance.
GoHealth depends on a concentrated group of major health plan partners and faces complex, frequently changing regulation from CMS, state insurance departments and privacy and telemarketing laws such as HIPAA, GLBA, CCPA and TCPA. Management highlights liquidity challenges, substantial indebtedness, restrictive credit facilities and prior going concern doubts, and has cut marketing, reduced 2025 Medicare Advantage activity, and implemented cost and workforce reductions.
As of June 30, 2025, non‑affiliate market value was approximately $32.9 million at a $5.55 share price. As of March 24, 2026, GoHealth had 16,225,250 Class A and 12,620,884 Class B shares outstanding and employed 850 people, after issuing WARN notices to about 487 employees in November 2025.
GoHealth, Inc. reported a sharp downturn in full-year 2025 results as it intentionally pulled back Medicare Advantage activity in a tougher market. Net revenues fell to $361.8 million, down 54.7% from 2024, while the company posted a net loss of $497.8 million, including $260.0 million of asset impairment charges.
Adjusted EBITDA swung from a $120.3 million profit in 2024 to a $35.1 million loss, and operating cash flow was a negative $121.9 million. Management emphasized a consumer-first strategy, higher retention, focus on Special Needs Plans, and targeted AI investments to lower acquisition costs and prepare for future industry consolidation.
GoHealth, Inc. reported that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities of $35 million. The notice also states GoHealth does not meet the alternative standards of at least $2.5 million in stockholders’ equity or $500,000 in net income from continuing operations.
The company’s shares will continue trading on The Nasdaq Global Market under the symbol GOCO while it has 180 calendar days, until September 14, 2026, to regain compliance. If compliance is not restored, Nasdaq may move to delist the stock, though GoHealth could appeal to a Nasdaq Hearings Panel. The company is evaluating options to regain compliance but cautions there is no assurance it will succeed.
GoHealth, Inc. has filed a resale registration covering up to 9,566,028 shares of its Class A common stock. These shares may be sold from time to time by the selling stockholder, Centerbridge, using methods such as brokered trades, underwritten offerings, private sales, or other transactions at market or negotiated prices.
GoHealth is not selling any shares in this offering and will not receive any proceeds; Centerbridge will receive all sale proceeds and pay any underwriting discounts and selling commissions. The registered shares include 5,386,178 shares issuable upon exchange of GoHealth Holdings, LLC interests and cancellation of an equal number of Class B shares. GoHealth’s Class A stock trades on Nasdaq under the symbol “GOCO,” and 16,093,116 Class A shares were outstanding as of December 11, 2025.
GoHealth, Inc. has filed an amended shelf registration to allow selling stockholders to resell up to 12,026,489 shares of its Class A common stock from time to time. These shares include 7,260,270 shares held or issuable to pre‑IPO investors through exchanges of LLC Interests and 4,766,219 shares issued to certain lenders in connection with credit agreement amendments and a new superpriority credit facility. The company itself is not selling any shares in this registration and will receive no proceeds from these resales, while the selling stockholders will bear any underwriting discounts and selling commissions. GoHealth’s Class A stock trades on Nasdaq under the symbol “GOCO,” and 16,093,116 shares of Class A common stock were outstanding as of November 13, 2025. The filing also summarizes GoHealth’s multi‑class capital structure, Series A convertible preferred stock, and governance and anti‑takeover provisions.
GoHealth, Inc. has filed a shelf registration statement covering the resale of up to 4,766,219 shares of its Class A common stock by a group of lending institutions that received the shares in a private placement. The company is not selling any shares in this offering and will not receive proceeds from sales made by these selling stockholders, who will bear any underwriting discounts and commissions.
The registered shares were issued as consideration for lenders entering into an amendment to GoHealth’s existing credit agreement and a new superpriority senior secured “priming” credit facility, which also coincided with board changes and the creation of a Transformation Committee focused on strategic alternatives. As context, GoHealth had 16,093,116 shares of Class A common stock outstanding as of November 13, 2025, and its Class A stock trades on Nasdaq under the symbol “GOCO”.
GoHealth, Inc. reported a sharp downturn for the quarter ended September 30, 2025. Net revenues were $34,186 thousand, and the company recorded a net loss of $313,918 thousand, driven by $206,163 thousand in impairment charges on indefinite and long‑lived assets. Operating expenses climbed to $322,103 thousand, resulting in a loss from operations of $287,917 thousand.
Liquidity and leverage were central themes. GoHealth amended its credit facilities and entered a Superpriority Senior Secured Credit Agreement totaling $115.0 million (including $80.0 million new‑money and $35.0 million roll‑up term loans) and issued 4,766,219 Class A shares to lenders tied to Amendment No. 14. Long‑term debt (net) rose to $581,844 thousand, and the company ended the quarter with cash of $32,076 thousand. Nine‑month operating cash flow was an outflow of $82,873 thousand.
Management disclosed a significant likelihood of failing to maintain covenant compliance within 12 months absent mitigating actions, and initiated cost measures including a Q4 2025 workforce reduction of approximately 487 employees. As of November 6, 2025, shares outstanding were 16,093,116 Class A and 12,620,884 Class B.